Congenital deafness gene therapies show promise : vimarsana.

Five studies, including at least three with ties to Boston, are using rival gene therapies to treat a hearing disorder caused by mutations in a single gene, called otoferlin.

Related Keywords

Yuncheng , Shanxi , China , Tarrytown , New York , United States , San Francisco , California , United Kingdom , Morocco , France , Paris , France General , Boston , Massachusetts , Anaheim , Shanghai , French , Jeffrey Holt , Yilai Shu , Manny Simons , Institut Pasteur , Aris Baras , Zheng Yi Chen , Margareta Kenna , Eli Lilly , Lijiao Zhao , New York Times , Centers For Disease , World Health Organization , Harvard Medical School , National Natural Science Foundation Of China , Association For Research , Regeneron Pharmaceuticals , Hospital Of Fudan University , Drug Administration , Disease Control , Mass Eye , Fudan University , National Natural Science Foundation , Shanghai Refreshgene , Harvard Medical , Boston Based Decibel Therapeutics , Shanghai Based Otovia Therapeutics , Aissam Dam , Boston Children , Healthcare Conference , ,